We serve N-Boc-L-glutamic Acid 5-Cyclohexyl Ester CAS:73821-97-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: N-Boc-L-glutamic Acid 5-Cyclohexyl Ester
CAS.NO:73821-97-3
Molecular Formula: C16H27NO6
Molecular Weight: 329.38900
Synonyms:
Boc-L-glutamic acid 5-cyclohexyl ester
Physical and Chemical Properties:
Density: 1.16g / cm3
Boiling point: 502.6ºC at 760 mmHg
Melting point: 54-57 ° C
Flash point: 257.8ºC
Refractive index: 1.497
Specification:
Appearance: White powder
Purity:≥98%
Residue on ignition:≤0.3%
Packing:25 kg/drum, can also be packaged according to customer requirements
StorageStorage at 2-8ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:Mainly used for amino acid infusion, due to special wettability, also used in cold cream, cosmetics.
Contact us for information like N-Boc-L-glutamic Acid 5-Cyclohexyl Ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Boc-L-glutamic acid 5-cyclohexyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Boc-L-glutamic acid 5-cyclohexyl ester Use and application,N-Boc-L-glutamic Acid 5-Cyclohexyl Ester technical grade,usp/ep/jp grade.
Related News: If the government does not close the border and heed their other demands by 9 p.m., union members handling emergency services would also strike, the union said.N-Boc-L-alaninol manufacturer Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.2,3,4,6-tetra-O-acetyl-D-glucono-1,5-lactone supplier Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.Methyl 4-boronobenzoate vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.
